NM_003221.4:c.540+24_540+31dupCAAACAAA
Variant summary
Our verdict is Uncertain significance. The variant received 0 ACMG points: 0P and 0B.
The NM_003221.4(TFAP2B):c.540+24_540+31dupCAAACAAA variant causes a intron change involving the alteration of a non-conserved nucleotide. No clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar.
Frequency
Genomes: not found (cov: 0)
Exomes 𝑓: 7.2e-7 ( 0 hom. )
Consequence
TFAP2B
NM_003221.4 intron
NM_003221.4 intron
Scores
Not classified
Clinical Significance
Not reported in ClinVar
Conservation
PhyloP100: 0.0710
Publications
0 publications found
Genes affected
TFAP2B (HGNC:11743): (transcription factor AP-2 beta) This gene encodes a member of the AP-2 family of transcription factors. AP-2 proteins form homo- or hetero-dimers with other AP-2 family members and bind specific DNA sequences. They are thought to stimulate cell proliferation and suppress terminal differentiation of specific cell types during embryonic development. Specific AP-2 family members differ in their expression patterns and binding affinity for different promoters. This protein functions as both a transcriptional activator and repressor. Mutations in this gene result in autosomal dominant Char syndrome, suggesting that this gene functions in the differentiation of neural crest cell derivatives. [provided by RefSeq, Jul 2008]
TFAP2B Gene-Disease associations (from GenCC):
- Char syndromeInheritance: AD Classification: DEFINITIVE, STRONG, SUPPORTIVE Submitted by: G2P, Labcorp Genetics (formerly Invitae), Orphanet
- familial patent arterial ductInheritance: AD Classification: SUPPORTIVE Submitted by: Orphanet
Genome browser will be placed here
ACMG classification
Classification was made for transcript
Our verdict: Uncertain_significance. The variant received 0 ACMG points.
Variant Effect in Transcripts
ACMG analysis was done for transcript: NM_003221.4. You can select a different transcript below to see updated ACMG assignments.
RefSeq Transcripts
| Selected | Gene | Transcript | Tags | HGVSc | HGVSp | Effect | Exon Rank | Protein | UniProt |
|---|---|---|---|---|---|---|---|---|---|
| TFAP2B | NM_003221.4 | MANE Select | c.540+24_540+31dupCAAACAAA | intron | N/A | NP_003212.2 |
Ensembl Transcripts
| Selected | Gene | Transcript | Tags | HGVSc | HGVSp | Effect | Exon Rank | Protein | UniProt |
|---|---|---|---|---|---|---|---|---|---|
| TFAP2B | ENST00000393655.4 | TSL:1 MANE Select | c.540+6_540+7insACAAACAA | splice_region intron | N/A | ENSP00000377265.2 | |||
| TFAP2B | ENST00000344788.7 | TSL:3 | c.534+6_534+7insACAAACAA | splice_region intron | N/A | ENSP00000342252.3 | |||
| TFAP2B | ENST00000489228.1 | TSL:2 | n.*6_*7insACAAACAA | downstream_gene | N/A |
Frequencies
GnomAD3 genomes Cov.: 0
GnomAD3 genomes
Cov.:
0
GnomAD4 exome AF: 7.21e-7 AC: 1AN: 1387016Hom.: 0 Cov.: 0 AF XY: 0.00000146 AC XY: 1AN XY: 684852 show subpopulations
GnomAD4 exome
AF:
AC:
1
AN:
1387016
Hom.:
Cov.:
0
AF XY:
AC XY:
1
AN XY:
684852
show subpopulations
African (AFR)
AF:
AC:
0
AN:
31270
American (AMR)
AF:
AC:
0
AN:
35926
Ashkenazi Jewish (ASJ)
AF:
AC:
0
AN:
25154
East Asian (EAS)
AF:
AC:
0
AN:
35816
South Asian (SAS)
AF:
AC:
0
AN:
79280
European-Finnish (FIN)
AF:
AC:
0
AN:
38342
Middle Eastern (MID)
AF:
AC:
0
AN:
5686
European-Non Finnish (NFE)
AF:
AC:
0
AN:
1077624
Other (OTH)
AF:
AC:
1
AN:
57918
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.475
Heterozygous variant carriers
0
0
1
1
2
2
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance
Age Distribution
Exome Het
Variant carriers
0
2
4
6
8
10
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
GnomAD4 genome Cov.: 0
GnomAD4 genome
Cov.:
0
ClinVar
Not reported inComputational scores
Source:
Name
Calibrated prediction
Score
Prediction
PhyloP100
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at
Publications
You must be logged in to view publications. This limit was set because tens of millions (!) of queries from AI bots are generated daily.